GHK-Cu (Copper Peptide): Uses, Evidence and Regulatory Status

GHK-Cu is a complex of copper(II) and the tripeptide glycyl-L-histidyl-L-lysine, a small molecule made of three amino acids that occurs naturally in human plasma, saliva and urine. It is one of the most studied peptides in dermatology, and on cosmetic ingredient labels it appears under the name copper tripeptide-1.

The peptide was first described by biochemist Loren Pickart, whose 1973 work showed that plasma from younger donors restored protein synthesis in aged liver tissue, with the active fraction later identified as GHK and shown to be most active when bound to copper. A defining feature of the molecule is that plasma levels of the parent GHK tripeptide fall sharply with age, dropping from around 200 nanograms per millilitre in young adults to roughly 80 nanograms per millilitre by age 60, a decline often linked to slower tissue repair.

GHK-Cu is what is sometimes called a dual-use compound. It exists both as a topical cosmetic active found in thousands of over-the-counter serums and creams, and as an injectable preparation sold in the research-chemical market and discussed in regenerative-medicine circles. These two forms sit in completely different regulatory boxes, which is the single most important thing to understand about it.

GHK-Cu appears to act at the level of gene expression rather than through a single receptor, which sets it apart from most repair peptides. Gene-profiling work summarised in Pickart and Margolina’s 2018 review reports that GHK can shift the activity of a very large number of human genes at once, broadly turning up genes tied to tissue repair, antioxidant defence and stem-cell activity while turning down genes associated with inflammation and tissue breakdown.

Copper delivery and enzyme support

Copper is a cofactor for enzymes that build and remodel the skin matrix, including lysyl oxidase, which cross-links collagen and elastin, and superoxide dismutase, an antioxidant enzyme. GHK acts as a carrier that binds copper and delivers it into cells in a controlled way. Notably, unlike simpler copper salts such as copper chloride, GHK-Cu has not been found to be cytotoxic or irritating when applied to skin, which is part of why it became a workable cosmetic ingredient.

Collagen, healing and angiogenesis

In animal and cell studies, GHK-Cu has been reported to stimulate synthesis of collagen, elastin and glycosaminoglycans, to support new blood vessel formation through growth factors such as VEGF and basic fibroblast growth factor, and to modulate transforming growth factor beta in a context-dependent way, encouraging repair in acute wounds while appearing to restrain excess scar-forming fibrosis in chronic settings. These mechanisms are why its research spans wound dressings, post-procedure skin recovery and hair-follicle biology.

The strongest GHK-Cu evidence is in topical cosmetic dermatology, where small controlled human studies exist; the evidence for injected GHK-Cu in humans is far thinner and rests largely on laboratory and animal work. Reading the evidence correctly means separating these tiers rather than treating them as one body of proof.

Application	Highest evidence tier	Notes
Aging skin (topical)	Small human trials	Firmness, density, fine lines over months of use
Wound healing (topical)	Mixed small trials + animal	Benefit at higher strengths; null result at 0.4 percent
Hair / scalp (topical)	Limited / anecdotal	Few studies; effective strength unestablished
Systemic / injectable use	Preclinical only	No completed human clinical trials for injected GHK-Cu

Skin and anti-aging data

A double-blind, placebo-controlled study led by James Leyden reported that a topical GHK-copper complex improved aging-skin parameters such as firmness, clarity and the appearance of fine lines over a course of regular use. Several smaller controlled studies have reported improvements in skin density and elasticity over a three to six month window. This is the area where GHK-Cu has its most credible human support.

Wound healing data

The wound-healing picture is more mixed and strength-dependent. Some small controlled work found that a higher GHK-Cu concentration reduced wound size and infection rates compared with placebo, while a separate trial using a lower 0.4 percent concentration on venous stasis ulcers found no benefit over placebo. That split is a useful reminder that formulation strength matters and that a positive headline result does not generalise to every preparation.

GHK-Cu’s legal status depends entirely on form. Topical GHK-Cu is treated as a cosmetic ingredient in most major markets, while injectable GHK-Cu falls under drug and compounding rules. The interim system that decides which peptides may be compounded is set out in our explainer on how the FDA’s compounding categories work.

Jurisdiction	Topical (cosmetic)	Injectable
United States	Legal as a cosmetic active; no FDA pre-approval	Not compoundable; PCAC review Feb 2027
United Kingdom	Permitted in cosmetics	No compounding pathway; research-use only
Australia	Permitted in cosmetics	Unapproved therapeutic good; research-use only

In the US, topical GHK-Cu listed as copper tripeptide-1 sits in the cosmetic-ingredient lane, which does not require drug approval, which is why so many serums contain it without regulatory difficulty. The injectable form is different. After the broader peptide reclassification of early 2026, the FDA’s April action placed GHK-Cu among a small group, alongside Melanotan II, cathelicidin LL-37, dihexa acetate and pegylated mechano growth factor, scheduled for a separate committee meeting expected before the end of February 2027 to decide whether they should be added to the 503A bulk drug substances list. The chronology behind that move is covered in our tracker of the 2026 peptide reclassification, and the broad national context in our overview of the wider US legal picture for peptides.

In the United Kingdom there is no compounding route equivalent to the US system, so injectable GHK-Cu sits in the research-use-only market with the usual supply-side risks, as set out in our guide to the UK’s peptide rules. The Australian position, where injectables are unapproved therapeutic goods, is covered in our look at how Australia treats peptides.

Topical GHK-Cu has a long track record of good tolerability, with the main reported issues being mild local reactions such as redness or irritation in sensitive users. Its safety record at cosmetic concentrations is one reason it became so widely adopted.

The picture is less settled for injectable use, where the concern is less about the peptide itself and more about copper load and product quality. Because GHK-Cu carries copper, systemic dosing raises theoretical questions about copper accumulation that have not been resolved in human trials. That copper content is also exactly what a buyer cannot verify in a research-chemical product: an underdosed, contaminated or mislabelled vial leaves both peptide identity and copper level unconfirmed, so third-party testing becomes the decisive check. We explain how to read it in our guide to spotting a credible peptide vendor and our walkthrough of what a certificate of analysis really proves.

GHK-Cu is usually grouped with other peptides marketed for recovery and tissue repair, even though it works through a different mechanism. For the wider category and how the major repair peptides compare, see our hub on recovery and repair peptides. The most discussed injury-repair peptide is covered in our write-up on the most studied injury-repair peptide, and another compound sharing GHK-Cu’s review timing is detailed in our guide to the antimicrobial peptide LL-37.